AI Terminal
Malin Corporation Plc
Report Publication Announcement • Aug 25, 2022
1959_rns_2022-08-25_87bdd26c-099c-4f68-9a0c-3f02ce0dc5b7.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1253X
Malin Corporation PLC
25 August 2022
Malin Corporation plc
Notice of 2022 Interim Results
Dublin-Ireland, 25 August 2022: Malin Corporation plc. (Euronext Growth Dublin:MLC) ("Malin" or "the Company"), a company investing in highly innovative life sciences companies, intends to announce its interim financial results and publish its interim report for the six month period ended 30 June 2022 at 07:00am Irish Standard Time / BST on Wednesday, 7 September 2022.
Darragh Lyons, Chief Executive Officer, will host a conference call at 12:00pm Irish Standard Time / BST on the day of publication. This call can be accessed as follows:
From Ireland dial: 01 53695 84
From the UK dial: 020 3936 2999
From the USA dial: 1 646 664 1960
From all other locations dial: +44 203 936 2999
Participant access code: 978118
The Company's results press release and presentation will be available on the Company's website from 07:00am Irish Standard Time / BST on 7 September 2022 at www.malinplc.com.
ENDS
About Malin Corporation plc
Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com
For further information contact:
ENDS
About Malin Corporation plc
Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com
For further information please contact:
Malin
Fiona Dunlevy, Company Secretary
Tel: +353 (0)1 901 5700
Davy Corporate Finance (Euronext Growth Listing Sponsor & Joint Broker)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
Liberum (Joint Broker)
Phil Walker / Ben Cryer
Tel: +44 (0) 20 3100 2000
Powerscourt (Media enquiries)
Eavan Gannon
Tel: +353 87 236 5973
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORFLFFETRISFIF